```
 => File .Biotech
=> s (Cyclosporin or Cyclosporin A or CSA)
L1      133253 (CYCLOSPORIN OR CYCLOSPORIN A OR CSA)

=> s (2-chlorodeoxyadenosine or 2-CDA or chloro(w)deoxyadenosine)
L2        3451 (2-CHLORODEOXYADENOSINE OR 2-CDA OR CHLORO(W) DEOXYADENOSINE)

=> s l1 and l2 and (combinat? or simultenous?(w)adminsitrat?)
L3         127 L1 AND L2 AND (COMBINAT? OR SIMULTENOUS?(W) ADMINSITRAT?)

=> s l3 and (chronic(w)allograft(w)reject?)
L4           2 L3 AND (CHRONIC(W) ALLOGRAFT(W) REJECT?)

=> d l4 1-2 bib ab

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:472340  CAPLUS
DN   139:30814
TI   Composition and method for treating chronic allograft
     rejection
IN   Salomon, Daniel R.; Cramer, Donald V.
PA   The Scripps Research Institute, USA
SO   PCT Int. Appl., 32 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2003049682     A2    20030619       WO 2002-US38628  20021205
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI US 2001-6562      A2    20011205
AB   The invention provides a compn. and a method for preventing or
     ameliorating the causes of chronic allograft
     rejection of a donor organ by a transplant recipient.  The method
     includes concomitant administration to the allograft recipient of
     therapeutically effective amts. of cyclosporin and 2-
     chlorodeoxyadenosine.  The compn. comprises a combination
     of cyclosporin and 2-chlorodeoxyadenosine in
     therapeutically effective amts. suitable for the practice of the method.

L4   ANSWER 2 OF 2  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
AN   2003-569072 [53]   WPIDS
DNC  C2003-153490
TI   Composition useful for treatment of chronic allograft
     rejection in mammal comprises cyclosporin, 2-
     chlorodeoxyadenosine and diluent, adjuvant or carrier.
DC   B02
IN   CRAMER, D V; SALOMON, D R
PA   (SCRI) SCRIPPS RES INST
CYC  102
PI   WO 2003049682 A2 20030619 (200353)* EN   16p
        RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
            MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW
```

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
ZM ZW

ADT WO 2003049682 A2 WO 2002-US38628 20021205
PRAI US 2001-6562 20011205
AB WO2003049682 A UPAB: 20030820
NOVELTY - A composition comprises **cyclosporin**, **2-chlorodeoxyadenosine** and a diluent, adjuvant or carrier.
ACTIVITY - Immunosuppressive; Antiarteriosclerotic.
The concomitant treatment of **cyclosporin** (**CSA**) and **2-chlorodeoxyadenosine** (CDA) were determined on circulating numbers of T cells using F344 rat model. F344 rats were treated with a composition (test) comprising **CSA** (5 mg/kg/day) and **2-CDA** (1 mg/kg/day). Untreated Lewis rats were used as control. The treated F344 rats received transplanted Lewis rat heart after 14 days and 90 days of treatment with the test composition. The reduction in number of lymph cells in the test treated rats was 6 (on day 14) and 7 (on day 90) respectively. The result showed a significant reduction in lymph cells as compared to untreated animals. The results indicated that the therapy increased efficacy of immunosuppression in ongoing, low-grade rejection by safely enhancing the overall level of immunosuppression, specifically targeting macrophage and antibody/B-cell mediated mechanisms of injury more effectively than current therapies.
MECHANISM OF ACTION - None given.
USE - In the manufacture of a medicament for preventing and ameliorating **chronic allograft rejection** in a transplanted organ e.g. heart and for preventing arterial atherosclerosis associated with **chronic allograft rejection** in mammal (claimed).
ADVANTAGE - The composition suppresses B-cell mediated response, which is a **combination** of mononuclear cell infiltration in myocardium, myocardial fibrosis and intimal proliferation of smooth muscle cells when the transplanted organ is heart. The composition provides an efficacious and improved method for preventing or ameliorating **chronic allograft rejection**. The composition reduces the risk of rejection in kidney, heart, lung and pancreas transplantation more than one or two years post transplant.
Dwg.0/8

=> s l3 and (treat? or prevent? or ameliorat? or inhibit?(w)allograft rejection)
6 FILES SEARCHED...
L5 114 L3 AND (TREAT? OR PREVENT? OR AMELIORAT? OR INHIBIT?(W) ALLOGRAFT REJECTION)

=> s l5 and (chronic)
L6 57 L5 AND (CHRONIC)

=> s l6 and (graft(w)reject?)
L7 15 L6 AND (GRAFT(W) REJECT?)

=> s l7 and (?heart? or ?cardio? or ?kidney? or ?pancreas? or ?liver? or ?organ?)
3 FILES SEARCHED...
LEFT TRUNCATION IGNORED FOR '?HEART?' FOR FILE 'BIOTECHDS'
LEFT TRUNCATION IGNORED FOR '?CARDIO?' FOR FILE 'BIOTECHDS'
LEFT TRUNCATION IGNORED FOR '?KIDNEY?' FOR FILE 'BIOTECHDS'
LEFT TRUNCATION IGNORED FOR '?PANCREAS?' FOR FILE 'BIOTECHDS'
LEFT TRUNCATION IGNORED FOR '?LIVER?' FOR FILE 'BIOTECHDS'
LEFT TRUNCATION IGNORED FOR '?ORGAN?' FOR FILE 'BIOTECHDS'
6 FILES SEARCHED...
L8 15 L7 AND (?HEART? OR ?CARDIO? OR ?KIDNEY? OR ?PANCREAS? OR ?LIVER? OR ?ORGAN?)
Left truncation is not valid in the specified search field in the

specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> Dup Rem L8
PROCESSING COMPLETED FOR L8
L9 15 DUP REM L8 (0 DUPLICATES REMOVED)

=> d l9 1-15 bib ab

L9 ANSWER 1 OF 15 USPATFULL on STN
AN 2004:4504 USPATFULL
TI Tumor necrosis factor receptor 2
IN Stanton, Jr., Vincent P., Belmont, MA, United States
PA Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6673908 B1 20040106
AI US 2001-968455 20011001 (9)
RLI Division of Ser. No. US 2000-649035, filed on 25 Aug 2000 Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on 1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US 2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252, filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on 9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US 1999-300747, filed on 26 Apr 1999, now abandoned
PRAI US 1999-131334P 19990426 (60)
US 1999-131191P 19990426 (60)
US 1999-121047P 19990222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Benzion, Gary; Assistant Examiner: Chakrabarti, Arun Kr.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 17463
AB The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of **treatment**. Methods of determining relevant variance information and additional methods of using such variance information are also described.

L9 ANSWER 2 OF 15 USPATFULL on STN
AN 2003:307263 USPATFULL
TI Coated medical devices for the **prevention** and **treatment** of vascular disease
IN Falotico, Robert, Belle Mead, NJ, UNITED STATES
PI US 2003216699 A1 20031120
AI US 2003-431059 A1 20030507 (10)
RLI Continuation-in-part of Ser. No. US 2001-850293, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-575480, filed on 19 May

2000, PENDING
PRAI US 2002-381986P 20020520 (60)
US 2000-204417P 20000512 (60)
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A drug and drug **delivery** system may be utilized in the **treatment** of vascular disease. A local **delivery** system is coated with rapamycin or other suitable drug, agent or compound and **delivered** intraluminally for the **treatment** and **prevention** of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local **delivery** of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

L9 ANSWER 3 OF 15 USPATFULL on STN
AN 2003:289405 USPATFULL
TI Coated vascular devices
IN Bosma, Gjalt, Opeinde, NETHERLANDS
van der Meulen, De heer Joost, Bergum, NETHERLANDS
PI US 2003204168 A1 20031030
AI US 2002-208581 A1 20020730 (10)
RLI Continuation-in-part of Ser. No. US 2002-136569, filed on 30 Apr 2002, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 3252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 4 OF 15 USPATFULL on STN
AN 2003:166521 USPATFULL
TI Methods of **treating** or **preventing** cell, tissue, and **organ** damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
IN Li, Haodong, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Grzegorzewski, Krzysztof J., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Patel, Vikram, Germantown, MD, UNITED STATES
Gentz, Reinder L., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003114379 A1 20030619

AI US 2002-261950 A1 20021002 (10)
RLI Division of Ser. No. US 2000-689693, filed on 13 Oct 2000, GRANTED, Pat. No. US 6495129 Division of Ser. No. US 2000-571013, filed on 15 May 2000, PENDING Division of Ser. No. US 1999-334951, filed on 17 Jun 1999, GRANTED, Pat. No. US 6451562 Continuation of Ser. No. US 1996-722723, filed on 30 Sep 1996, ABANDONED Continuation of Ser. No. US 1996-722719, filed on 30 Sep 1996, GRANTED, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, ABANDONED Continuation of Ser. No. US 1994-208339, filed on 8 Mar 1994, GRANTED, Pat. No. US 5504003
PRAI US 1999-159362P 19991014 (60)
US 1999-164059P 19991108 (60)
US 1999-172063P 19991223 (60)
US 2000-189048P 20000314 (60)
US 2000-199142P 20000424 (60)
US 2000-211458P 20000613 (60)
US 2000-212658P 20000619 (60)
US 1996-27299P 19960930 (60)
US 1996-27300P 19960930 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 73 Drawing Page(s)
LN.CNT 14465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine .beta.8 (CK.beta.8 or ckb-8)), as well as MPIF-1 polypeptide itself, as are vectors, host cells and recombinant methods for producing the same.

L9 ANSWER 5 OF 15 USPATFULL on STN
AN 2003:120747 USPATFULL
TI Blood cell deficiency **treatment** method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)

US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to **treat** a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the **treatment** method.

L9 ANSWER 6 OF 15 USPATFULL on STN
AN 2003:94014 USPATFULL
TI Coated medical devices
IN Davila, Luis A., Pleasanton, CA, UNITED STATES
Wilson, David J., Branchburg, NJ, UNITED STATES
PI US 2003065377 A1 20030403
AI US 2002-136569 A1 20020430 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 7 OF 15 USPATFULL on STN
AN 2003:93983 USPATFULL
TI Drug releasing anastomosis devices and methods for **treating** anastomotic sites

IN Evens, Carl J., Branchburg, NJ, UNITED STATES
Weedock, Kevin, Princeton, NJ, UNITED STATES
PI US 2003065346 A1 20030403
AI US 2002-274782 A1 20021021 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 3454
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 8 OF 15 USPATFULL on STN
AN 2003:93982 USPATFULL
TI Anastomosis devices and methods for **treating** anastomotic sites
IN Weadock, Kevin, Princeton, NJ, UNITED STATES
PI US 2003065345 A1 20030403
AI US 2002-274770 A1 20021021 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 3485
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 9 OF 15 USPATFULL on STN
AN 2003:87268 USPATFULL
TI Coated medical devices for the **treatment** of vascular disease
IN Falotico, Robert, Belle Mead, NJ, UNITED STATES
Spaltro, John, Asbury, NJ, UNITED STATES
PI US 2003060877 A1 20030327
AI US 2002-122978 A1 20020415 (10)
RLI Continuation-in-part of Ser. No. US 2001-962496, filed on 25 Sep 2001, PENDING

DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 2858
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological **organism**'s reaction to the introduction of the medical device to the **organism**, the medical device in **combination** with one or more therapeutic drugs, agents and/or compounds may be utilized to **treat** various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to **treat** the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective **treatment**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 10 OF 15 USPATFULL on STN
AN 2003:86817 USPATFULL
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)
DT Utility
FS APPLICATION

LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16.alpha.-bromo-3 .beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, **ameliorate** symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

L9 ANSWER 11 OF 15 USPATFULL on STN
AN 2003:95978 USPATFULL
TI Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
IN Slavin, Shimon, Jerusalem, ISRAEL
PA Hadash Medical Research Services and Development Ltd., Jerusalem, ISRAEL (non-U.S. corporation)
Baxter International Inc., Deerfield, IL, United States (U.S. corporation)
PI US 6544787 B1 20030408
AI US 1997-995049 19971114 (8)
PRAI US 1997-37024P 19970130 (60)
US 1996-30833P 19961115 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Parkin, Jeffrey S.
LREP G. E. Ehrlich Ltd.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1542
AB Serious hematologic malignancies are **treated** through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) **treatment** regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin). After this, a donor-derived allogeneic stem cell preparation is administered to the patient. Patients **treated** according to the claimed invention develop donor-specific unresponsiveness and relatively fewer complications as compared to standard M/L conditioning regimens. The claimed methodologies should prove useful in the **treatment** of a number of hematologic malignancies such as **chronic** myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic

leukemia, and non-Hodgkin's lymphoma.

L9 ANSWER 12 OF 15 USPATFULL on STN
AN 2002:243987 USPATFULL
TI Coated medical devices
IN Lentz, David Christian, Weston, FL, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo, Whitehouse Station, NJ, UNITED STATES
Weadock, Kevin, Princeton, NJ, UNITED STATES
PI US 2002133183 A1 20020919
AI US 2001-966447 A1 20010928 (9)
RLI Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 13 OF 15 USPATFULL on STN
AN 2002:206886 USPATFULL
TI Medical devices, drug coatings and methods for maintaining the drug coatings thereon
IN Davila, Luis A., Pleasanton, CA, UNITED STATES
Lentz, David Christian, Weston, FL, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Mendez, Jorge Orlando, Miami, FL, UNITED STATES
Narayanan, Pallassana V., Belle Mead, NJ, UNITED STATES
Pelton, Alan Roy, Fremont, CA, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scheidt, Karl K., Pembroke Pines, FL, UNITED STATES
Scopelianos, Angelo George, Whitehouse Station, NJ, UNITED STATES
Shaw, William Douglas, JR., Miami, FL, UNITED STATES
Silver, James H., Redwood City, CA, UNITED STATES
Spaltro, John, Asbury, NJ, UNITED STATES
Trepanier, Christine, Fremont, CA, UNITED STATES
Wilson, David J., Ft. Lauderdale, FL, UNITED STATES
PI US 2002111590 A1 20020815
AI US 2001-962496 A1 20010925 (9)
RLI Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-884729, filed on 19 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING
DT Utility
FS APPLICATION

LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 99
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned.

L9 ANSWER 14 OF 15 USPATFULL on STN
AN 2002:98835 USPATFULL
TI Coated medical devices and sterilization thereof
IN Bodnar, Stanko, Whitehouse Station, NJ, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo, Whitehouse Station, NJ, UNITED STATES
PI US 2002051730 A1 20020502
AI US 2001-966783 A1 20010928 (9)
RLI Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological **organism**'s reaction to the introduction of the medical device to the **organism**. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological **organism**'s reaction to the introduction of the medical device to the **organism**. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until **delivered** and positioned. An efficient and effective sterilization process is also set forth.

L9 ANSWER 15 OF 15 USPATFULL on STN
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6495129 B1 20021217

AI US 2000-689693 20001013 (9)
RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719, filed on 30 Sep 1996, now patented, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part of Ser. No. US 208339
PRAI US 2000-212658P 20000619 (60)
US 2000-211458P 20000613 (60)
US 2000-199142P 20000424 (60)
US 2000-189048P 20000314 (60)
US 1999-172063P 19991223 (60)
US 1999-164059P 19991108 (60)
US 1999-159362P 19991014 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mertz, Prema
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 102 Drawing Figure(s); 73 Drawing Page(s)
LN.CNT 14198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine .beta.8 (CK.beta.8 or ckb-8)), as well as MPIF-1 polypeptide itself, as are vectors, host cells and recombinant methods for producing the same.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:01:26 ON 22 JAN 2004